Renpeng Gu
About Renpeng Gu
Renpeng Gu is a Scientist I specializing in Molecular and Cell Biology at SalioGen Therapeutics, with a strong academic background in Materials Science and Polymer Engineering. He has contributed to several innovative projects, including DNA binding domain strategies and genome editing techniques.
Work at SalioGen Therapeutics
Renpeng Gu serves as Scientist I in Molecular & Cell Biology at SalioGen Therapeutics, a position he has held since 2021. His work focuses on advancing molecular biology techniques and contributing to the development of innovative therapeutic strategies. SalioGen Therapeutics is located in Woburn, Massachusetts, and is recognized for its efforts in gene therapy and genome editing.
Education and Expertise
Renpeng Gu obtained a Doctor of Philosophy (PhD) in Materials Science from Duke University, where he studied from 2012 to 2018. He also holds a Master of Science (MS) in Chemical and Biomolecular Engineering from Western University, completed between 2010 and 2012. His undergraduate education includes a Bachelor of Engineering (BEng) in Polymer Materials and Engineering from Zhejiang University, where he studied from 2006 to 2010.
Background
Renpeng Gu has a diverse background in research and academia. He began his research career at Zhejiang University, where he worked as a Research Assistant in various laboratories from 2008 to 2010. He later served as a Postdoctoral Associate at Duke University from 2012 to 2021, contributing to the Mechanical Engineering and Materials Science Department. His experience also includes a Postdoctoral Research Fellowship at Boston College from 2019 to 2021.
Research Contributions
Renpeng Gu has made significant contributions to the field of molecular biology and materials science. He developed a novel genome editing strategy using recombinant transcription activator-like effectors (TALE) and unnatural amino acids for site-specific DNA alkylation. Additionally, he created a display strategy utilizing DNA binding domains (DBD) to enhance specificity and affinity for targeted DNA sequences, and innovated a DBD dimer-diazirine design to improve photocrosslinking efficiency in cell lysates.